Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Utility of PET in Breast Cancer.

Norbert Avril1, Marcus Schelling, Jorg Dose

  • 1Departments of Nuclear Medicine, Technische Universität München, Munich, Germany

Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T
|October 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fetal Cardiac Magnetic Resonance Imaging in Left-Sided Diaphragmatic Hernia.

JACC. Case reports·2025
Same author

Combined DCE-MRI- and FDG-PET enable histopathological grading prediction in a rat model of hepatocellular carcinoma.

European journal of radiology·2020
Same author

A 3D Deep Residual Convolutional Neural Network for Differential Diagnosis of Parkinsonian Syndromes on <sup>18</sup>F-FDG PET Images.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2020
Same author

Diagnostic performance of quantitative and qualitative parameters for the diagnosis of aortic graft infection using [<sup>18</sup>F]-FDG PET/CT.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2020
Same author

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by <sup>18</sup>F- or <sup>68</sup>Ga-Labeled rhPSMA Inhibitors.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2019
Same author

Correction to: In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography.

EJNMMI research·2019
Same journal

Changes in FDG Tumor Uptake during and after Fractionated Radiation Therapy in a Rodent Tumor Xenograft.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2003
Same journal

Diabetes Decreases FDG Accumulation in Primary Lung Cancer.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2003
Same journal

Relationship between Gastrointestinal F-18-fluorodeoxyglucose Accumulation and Gastrointestinal Symptoms in Whole-Body PET.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2003
Same journal

FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2003
Same journal

Electronic Generators for the Production of Positron-Emitter Labeled Radiopharmaceuticals. Where Would PET Be Without Them?

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2003
Same journal

Detection of Vasculitis by FDG-PET Using MCD.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2003
See all related articles

Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) aids in early breast cancer detection and staging. This metabolic imaging technique helps monitor chemotherapy effectiveness, identifying nonresponders to avoid ineffective treatments.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Breast cancer is a leading cause of cancer death in women, with early detection crucial for curability.
  • Mammography is a primary screening tool, but limitations exist in diagnosing and staging breast cancer accurately.
  • Positron emission tomography (PET) offers metabolic imaging to overcome diagnostic and staging challenges.

Purpose of the Study:

  • To evaluate the role of F-18 fluorodeoxyglucose (FDG) PET in breast cancer diagnosis, staging, and treatment monitoring.
  • To highlight the clinical utility of FDG-PET in identifying metastatic axillary lymph nodes and assessing treatment response.

Main Methods:

  • Utilizing F-18 fluorodeoxyglucose (FDG) as a radiotracer for PET imaging.
  • Employing whole-body PET imaging for comprehensive staging of breast cancer patients.

Related Experiment Videos

  • Analyzing metabolic signals from tumor tissue to assess chemotherapy effects.

    • Main Results:

    • FDG-PET can detect breast cancers larger than 1 cm in diameter.
    • It accurately identifies axillary lymph node metastases in locally advanced disease.
    • FDG-PET effectively differentiates between chemotherapy responders and nonresponders early in treatment.

    Conclusions:

    • FDG-PET is a valuable tool for accurate breast cancer staging and early detection.
    • Metabolic imaging with FDG-PET enables monitoring of chemotherapy response.
    • Identifying nonresponders via FDG-PET can help personalize treatment, reducing toxicity and improving outcomes.